Skip to content

Acute Kidney Injury Among Pediatric Cancer Patients At South Egypt Cancer Institute

Acute Kidney Injury Among Pediatric Cancer Patients At South Egypt Cancer Institute

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06081608
Enrollment
2
Registered
2023-10-13
Start date
2023-11-01
Completion date
2024-09-01
Last updated
2023-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To Determine the Cumulative Incidence of AKI Using KDIGO Criteria in Pediatric Patients With Malignancy in South Egypt Cancer Institute (SECI)

Brief summary

Cancer is the second most frequent cause of premature death in children. The incidence of pediatric cancer varies by region and country, but it is generally considered rare with an estimated 300,000 new cases diagnosed worldwide. Acute kidney injury in pediatric cancer patients refers to the sudden and often temporary loss of renal function, which can lead to a variety of complications if not treated correctly.

Detailed description

* Primary: To determine the cumulative incidence of AKI using KDIGO criteria in pediatric patients with malignancy in South Egypt Cancer Institute (SECI) * Secondary: 1. Incidence of Hospital-acquired and community-acquired AKI 2. Asses the risk factors of the incidence of AKI 3. To determine in-hospital outcome (time to in-hospital death, length of hospital stay, and time to kidney recovery) of AKI. This is a prospective study that will be carried out in the Paediatric Oncology and Haematological Malignancies Department including patients diagnosed with malignant tumours and hospitalized from 1st April 2023 for one year duration.

Interventions

DIAGNOSTIC_TESTkidney function test

blood sample for kidney function test

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Days to 18 Years

Inclusion criteria

* • Children of both sexes (aged from 1 month to 18 years at diagnosis) * Patients with either hematological malignancies or solid tumors admitted to the Paediatric Oncology and Haematological Malignancies Department

Exclusion criteria

* Children who had an unconfirmed cancer diagnosis. * Children more than 18 years at diagnosis. * Children with preexisting chronic kidney disease (CKD) that defined as the presence of structural or functional kidney damage that persist over minimum of three month * The patient underwent hematopoietic stem cell transplantation. Patients with 1 s.Cr level. * Patient underwent renal transplant.

Design outcomes

Primary

MeasureTime frame
To determine the cumulative incidence of AKI using KDIGO criteria in pediatric patients with malignancy in South Egypt Cancer Institute (SECI)from November 2023 till November 2024

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026